| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
mTOR
Zederone is a natural sesquiterpenoid compound from Curcuma species. While specific molecular targets have not been extensively characterized, compounds from Curcuma species are known to modulate various signaling pathways, including NF-κB, MAPK, and PI3K/AKT pathways. |
|---|---|
| ln Vitro |
In vitro, zederone and related compounds from Curcuma species have been shown to exhibit anti-inflammatory, antioxidant, and anticancer activities. These activities are typically mediated through the modulation of signaling pathways such as NF-κB, MAPK, and PI3K/AKT, as well as through the induction of apoptosis and inhibition of cell proliferation.
|
| ln Vivo |
In vivo, zederone and related compounds from Curcuma species have been studied for their potential therapeutic applications in various diseases, including cancer, inflammation, and metabolic disorders.
|
| Enzyme Assay |
In vitro assays for zederone are performed to evaluate its biological activities. Anti-inflammatory activity is assessed by measuring the inhibition of pro-inflammatory cytokine production or NF-κB activation. Antioxidant activity is assessed by measuring the scavenging of free radicals or the inhibition of lipid peroxidation. Anticancer activity is assessed by measuring the inhibition of cell proliferation and the induction of apoptosis in cancer cell lines.
|
| Cell Assay |
In vitro cell-based assays are conducted to evaluate the effects of zederone on cell viability, inflammation, and oxidative stress. Cells are treated with zederone, and cell viability is assessed using standard assays such as MTT or CCK-8. Inflammatory markers such as TNF-α, IL-6, and IL-1β are measured by ELISA. Oxidative stress markers such as ROS and MDA are measured using fluorescent or colorimetric assays.
|
| Animal Protocol |
In vivo animal studies with zederone would be conducted in models of inflammation, cancer, or metabolic disorders to evaluate its therapeutic potential. The compound could be administered via oral or intraperitoneal routes. Its effects on disease progression, inflammatory markers, and survival would be assessed.
|
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data are publicly available for zederone. As a natural sesquiterpenoid, its oral bioavailability may be limited. Its pharmacokinetic properties would be studied in preclinical models.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are publicly available for zederone. As a natural product, it is generally considered to have low toxicity, but comprehensive toxicological studies would be required for therapeutic development.
|
| References | |
| Additional Infomation |
(3R,5S,8E)-5,9,14-trimethyl-4,12-dioxatricyclo[9.3.0.03,5]tetradec-1(11),8,13-trien-2-one is a sesquiterpene compound. (3R,5S,8E)-5,9,14-trimethyl-4,12-dioxatricyclo[9.3.0.03,5]tetradec-1(11),8,13-trien-2-one has been reported in turmeric (Curcuma ochrorhiza) and turmeric (Curcuma longa), and relevant data are available.
Zederone (zedoary epoxy ketone) is a natural sesquiterpenoid compound found in the rhizomes of Curcuma species, including Curcuma zedoaria and Curcuma longa. It has been studied for its potential therapeutic applications, including anti-inflammatory, antioxidant, and anticancer activities. Zederone is a valuable research tool for studying the pharmacological activities of sesquiterpenoids. The compound is not approved for human therapeutic use and is strictly for research purposes. |
| Molecular Formula |
C15H18O3
|
|---|---|
| Molecular Weight |
246.30
|
| Exact Mass |
246.125
|
| CAS # |
7727-79-9
|
| PubChem CID |
71694446
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
365.3±42.0 °C at 760 mmHg
|
| Melting Point |
153.4-153.9℃ (acetone hexane )
|
| Flash Point |
174.7±27.9 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.528
|
| Source |
Originated from plants: Zingiberaceae Curcuma elata Roxb.
|
| LogP |
3.58
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
18
|
| Complexity |
401
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C/C/1=C\CC[C@]2([C@@H](O2)C(=O)C3=C(C1)OC=C3C)C
|
| InChi Key |
CVIVANCKIBYAOP-WSQYCBKMSA-N
|
| InChi Code |
InChI=1S/C15H18O3/c1-9-5-4-6-15(3)14(18-15)13(16)12-10(2)8-17-11(12)7-9/h5,8,14H,4,6-7H2,1-3H3/b9-5+/t14-,15-/m0/s1
|
| Chemical Name |
(3R,5S,8E)-5,9,14-trimethyl-4,12-dioxatricyclo[9.3.0.03,5]tetradeca-1(11),8,13-trien-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~203.0 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.15 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.15 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (10.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0601 mL | 20.3004 mL | 40.6009 mL | |
| 5 mM | 0.8120 mL | 4.0601 mL | 8.1202 mL | |
| 10 mM | 0.4060 mL | 2.0300 mL | 4.0601 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
